Michael A Metzger's Net Worth
$11.2 Million
Who is Michael A Metzger?
Michael A Metzger has an estimated net worth of $11.2 Million. This is based on reported shares across multiple companies, which include Syndax Pharmaceuticals Inc, CTI BIOPHARMA CORP, Regado Biosciences Inc, RESPONSE GENETICS INC, and Pyxis Oncology, Inc..
SEC CIK
Michael A Metzger's CIK is 0001507220
Past Insider Trading and Trends
2021 was Michael A Metzger's most active year for acquiring shares with 17 total transactions. Michael A Metzger's most active month to acquire stocks was the month of January. 2022 was Michael A Metzger's most active year for disposing of shares, totalling 32 transactions. Michael A Metzger's most active month to dispose stocks was the month of June. 2023 saw Michael A Metzger paying a total of $11,743,518.42 for 495,959 shares, this is the most they've acquired in one year. In 2020 Michael A Metzger cashed out on 230,000 shares for a total of $2,375,922.50, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Syndax Pharmaceuticals Inc (SNDX) Snapshot price: $19.1
Chief Executive OfficerMichael A Metzger owns 163,909 units of Common Stock which is worth $3,130,661.90. From 2016 to 2024 Michael A Metzger acquired a total of 701,579 shares in Syndax Pharmaceuticals Inc at a cost of $3,928,378.34, Michael also disposed a total of 537,670 shares of Syndax Pharmaceuticals Inc equalling to $10,996,865.37.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +828.19% | 146.25K |
—
|
—
| 163.91K |
Feb 7
| |||
Form 4
|
—
|
0
|
$17.01 | -$126,678.81 | 17.66K |
Scheduled
|
Feb 6
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 2
| |||
Form 4
|
—
|
0
|
$17.03 | -$268,162.09 | 17.66K |
Scheduled
|
Oct 6
| ||
Form 4
|
—
|
0
|
$16.90 | -$548,735.87 | 17.66K |
Scheduled
|
Sep 30 - Oct 4
| ||
Form 4
|
—
|
0
|
$13.72 | -$463,771.99 | 17.66K |
Scheduled
|
Jul 25
| ||
Form 4
|
—
|
0
|
$13.73 | -$222,011.75 | 17.66K |
Scheduled
|
Jul 6 - Jul 7
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 2
| |||
Form 4
|
—
|
0
|
$13.79 | -$1,050,500.53 | 17.66K |
Scheduled
|
Dec 16 - Dec 20
| ||
Form 4
|
—
|
0
|
$12.74 | -$462,276.28 | 17.66K |
Scheduled
|
Dec 13
| ||
Form 4
|
—
|
0
|
$13.18 | -$728,959.58 | 17.66K |
Scheduled
|
Oct 25 - Oct 26
| ||
Form 4
|
—
|
0
|
$13.36 | -$300,885.45 | 17.66K |
Scheduled
|
Sep 27
| ||
Form 4
|
—
|
0
|
$13.21 | -$439,607.06 | 17.66K |
Scheduled
|
Sep 20 - Sep 22
| ||
Form 4
|
—
|
0
|
$13.16 | -$726,832.97 | 17.66K |
Scheduled
|
Sep 13 - Sep 14
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 3
| |||
Form 4
|
—
|
0
|
$13.70 | -$194,799.00 | 17.66K |
Scheduled
|
Feb 1
| ||
Form 4
|
—
|
0
|
$15.09 | -$236,512.50 | 17.66K |
Scheduled
|
Dec 1
| ||
Form 4
|
—
|
0
|
$13.76 | -$1,311,410.00 | 17.66K |
Scheduled
|
Nov 4
| ||
Form 4
| +564.12% | 15K |
—
|
—
| 17.66K |
Feb 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 4
| |||
Form 4
|
∞
| 2.66K |
$4.76 | $12,656.84 | 2.66K |
Jan 31 - Feb 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 6
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CTI BIOPHARMA CORP No price found
InvestorMichael A Metzger used to own units in Common Stock but no longer holds any shares there. In the year 2017 Michael A Metzger filed a total of 14 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 26
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 5
| |||
Form 4
|
—
|
0
|
$3.27 | -$424,047.47 |
0
|
Scheduled
|
Nov 8
| ||
Form 4
| -100.00% | -20.12K |
$6.51 | -$130,994.92 |
0
|
Scheduled
|
Jul 7
| ||
Form 4
|
—
|
0
|
$3.46 | -$479,106.51 | 20.12K |
Scheduled
|
Jul 5
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 17
| |||
Form 4
|
∞
| 20.12K |
—
|
—
| 20.12K |
Jan 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Regado Biosciences Inc No price found
President & CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Dec 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
RESPONSE GENETICS INC No price found
InvestorMichael A Metzger owns 1,000 units of Common Stock, par value $0.01 per share. From 2010 to 2012 Michael A Metzger acquired a total of 1,000 shares in RESPONSE GENETICS INC at a cost of $1,500.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 30
| |||
Form 4
|
∞
| 1K |
$1.50 | $1,500.00 | 1K |
Feb 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Pyxis Oncology, Inc. (PYXS) Snapshot price: $3.45
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||